You are here

Front opens in US biotech price war

Express Scripts, largest manager of prescription drug plans for US employers, takes increasingly aggressive stance in price negotiations with pharma firms

BT_20141224_MED24_1426083.jpg
Express Scripts Holding Co will shun Gilead Sciences Inc's blockbuster US$1,000-a-pill hepatitis C treatment in favour of a cheaper drug Viekira Pak from AbbVie Inc.

New York

THE biotechnology industry's two-year run of riches is at risk after a decision by the biggest US drug manager to block one of the best-selling products in history.

Since the start of 2013, the Standard & Poor's Biotechnology Index has gained 134 per cent, almost...

sentifi.com

Market voices on: